Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 210 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis September 15, 2025 Her Massive Weight Loss Helped Her Feel A Lump In Her... January 24, 2020 Load more HOT NEWS How Anxiety Impacts People With Cancer and How to Cope Stopping neuropathy: One of chemotherapy’s most challenging side effects A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients...
